Dog Vaccines Market Report 2026

Dog Vaccines Market Overview

• Dog Vaccines market size has reached to $3.8 billion in 2025 • Expected to grow to $5.44 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Zoonotic Threats Fuel Surge In Demand For Dog Vaccines, Driving Market Growth • Market Trend: Focus On Development Of Next Generation And Recombinant Vaccine Platforms To Enhance Canine Disease Prevention • Asia-Pacific was the largest region in 2025.

What Is Covered Under Dog Vaccines Market?

Dog vaccines refer to injections that are given to dogs in series starting at the puppy stage and continuing into adulthood. These vaccines are used to introduce tiny amounts of a virus particle to induce an immune response in the body. In this way, if the dog's body is exposed to this bacteria or virus, it can mount an immune response and prevent sickness. The main types of dog vaccines include attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. An attenuated live vaccine is a vaccine created by reducing the virulence of a pathogen that is still kept viable. They are administered through subcutaneous, intramuscular, and intranasal routes for various applications of below 6 months and above 6 months dogs.

What Is The Dog Vaccines Market Growth Forecast?

The dog vaccines market size is expected to see strong growth in the next few years. It will grow to $5.44 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancements in recombinant and dna vaccines, increasing focus on canine preventive healthcare, expansion of veterinary immunization programs, rising investments in canine health r&d, adoption of digital tools for vaccination tracking. Major trends in the forecast period include increasing vaccination awareness among dog owners, development of multivalent vaccines for canines, rising adoption of preventive veterinary care, expansion of pediatric and adult canine vaccine programs, growth in veterinary clinics offering comprehensive immunization services.

Global Dog Vaccines Market Segmentation

1) By Type: Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines 2) By Route Of Administration: Subcutaneous, Intramuscular, Intranasal 3) By Application: Below 6 Months, Above 6 Months Subsegments: 1) By Attenuated Live Vaccines: Canine Parvovirus Vaccine, Canine Distemper Vaccine, Canine Adenovirus Vaccine 2) By Conjugate Vaccines: Canine Leptospira Vaccine, Canine Bordetella Vaccine 3) By Inactivated Vaccines: Canine Parvovirus Vaccine, Canine Influenza Vaccine 4) By Subunit Vaccines: Canine Lyme Disease Vaccine, Canine Parainfluenza Vaccine 5) By Toxoid Vaccines: Canine Leptospirosis Toxoid Vaccine 6) By DNA Vaccines: Canine Melanoma Vaccine 7) By Recombinant Vaccines: Canine Lyme Disease Recombinant Vaccine, Canine Bordetella Recombinant Vaccine

What Is The Driver Of The Dog Vaccines Market?

The growing prevalence of zoonotic diseases is expected to propel the growth of the dog vaccines market going forward. Zoonotic diseases, also known as zoonoses, are infectious diseases that can be transmitted naturally between animals and humans and vice versa. Zoonotic diseases are rising due to the expansion of human populations into wildlife habitats, which increases contact with animals and the likelihood of disease transmission. Dog vaccines play a crucial role in preventing the transmission of zoonotic diseases from dogs to humans and contribute to the overall public health efforts to control and manage zoonotic infections. For instance, in February 2023, according to the Council on Foreign Relations (CFR), a US-based independent, nonpartisan member organization, think tank, and publisher, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases have zoonotic origins. Worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the growing prevalence of zoonotic diseases is driving the growth of the dog vaccines industry.

Key Players In The Global Dog Vaccines Market

Major companies operating in the dog vaccines market are Vetoquinol S.A., Boehringer Ingelheim GmbH, Ceva Sante Animale, Heska Corporation, Merck & Co. Inc., Virbac Animal Health Pvt. Ltd., Elanco Animal Health Incorporated, Zoetis Inc., CZ Vaccines, Indian Immunologicals Ltd., Meiji Holdings Co. Ltd., Bioveta A.S., Phibro Animal Health Corporation, Hester Biosciences Limited, Dechra Pharmaceuticals PLC, Norbrook Inc., Biogenesis Bago SA, Vaxxinova India Private Limited, Bimeda Animal Health Ltd., Lohmann Animal Health GmbH, Biovac Ltd., Zenex Animal Health India Pvt. Ltd., Instituto Rosenbusch S.A.

Global Dog Vaccines Market Trends and Insights

Major companies operating in the dog vaccines market are focusing on developing innovative vaccine technologies such as next-generation recombinant and RNA-based vaccines to improve immune response, safety, and duration of protection in companion animals. Next-generation canine vaccines are designed to stimulate targeted immunity using advanced platforms, while recombinant vaccines use specific antigens to reduce adverse reactions and enhance efficacy. For instance, in June 2024, according to Merck & Co. Inc.’s MSD Animal Health, a US-based animal health company, the United States Department of Agriculture (USDA) approved Nobivac NXT Canine Influenza Virus (CIV), a next-generation RNA-particle vaccine for dogs, marking a significant advancement in canine influenza prevention by offering rapid onset of immunity and improved protection against circulating virus strains.

What Are Latest Mergers And Acquisitions In The Dog Vaccines Market?

In September 2024, Boehringer Ingelheim, a Germany-based company, operates in both human and animal health sectors, acquired Saiba Animal Health AG for an undisclosed amount. This acquisition enhances Boehringer Ingelheim's research and development capabilities in the animal health sector, particularly focusing on innovative therapeutic vaccines for pets, which addresses chronic diseases such as allergies, inflammation, and pain. Saiba Animal Health AG, a Switzerland-based company that provides dog vaccines.

Regional Outlook

Asia-Pacific was the largest region in the dog vaccines market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Dog Vaccines Market?

The dog vaccines market consists of sales of vaccines for dogs including core dog vaccines, and non-core dog vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.